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 Every 66 seconds someone in the United States develops Alzheimer’s disease. 
Today, 24 million people are living with the disease. Alzheimer’s is a terminal illness 
without a cure. Unfortunately, no non-invasive diagnostic technique exists that can 
definitively diagnosis an individual with early-stage Alzheimer’s. Most often, those that 
are given “probable” diagnoses are properly diagnosed only after irreversible damage 
has occurred in the brain. An earlier diagnosis would have brought these patients a 
variety of benefits. An early diagnosis means that a patient is afforded earlier access to 
available treatments, is able to build a care team, can investigate support services and 
can enroll in potentially effective clinical trials. Aside from physical benefits, early-
diagnosed patients can better prepare emotionally, socially, financially and legally for 
the toll the disease takes on the body and mind. Thus, an unmet need exists to develop 
a diagnostic technique that can definitively diagnose Alzheimer’s as early as possible. 
 Altered brain energetics and metabolism have been shown to be associated with 
Alzheimer’s disease. These changes occur alongside alterations of the normal cycles of 
fission and fusion of mitochondria in neurons, which together are referred to as 
mitochondrial dynamics. Changes in mitochondrial dynamics lead to inadequate 
cellular energy production, ultimately inducing the loss in synaptic activity and 
neuronal death associated with Alzheimer’s. 
  This research involved creating a Monte Carlo model that simulates the 
mitochondrial morphological changes that occur in response to the progression of 
neurodegenerative diseases like Alzheimer’s. Simultaneously, the model predicts light 
scattering profiles for a specific mitochondrion as it undergoes the structural changes 
associated with altered mitochondrial dynamics.  
 This model serves to provide useful insight into optical imaging of mitochondrial 
dynamics and how optical imaging technology/processing might be optimized to 
provide useful diagnostic information for Alzheimer’s and other forms of dementia.
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1   Introduction 
 
1.1   Undergraduate Motivation 
 
 In my third year at the University of Texas at Austin, I took two semesters of Quantitative 
Engineering Physiology. The first semester was co-taught and one of my professors was Dr. 
Rylander, who is my thesis advisor and lab director. One of the units Dr. Rylander taught was 
neurology and neurological diseases, and I found that specific unit to be the most exciting. In 
class, we discussed several imaging techniques, including Optical Coherence Tomography 
(OCT), and how those techniques affect diagnosis and treatment of diseases. After the class 
ended, I contacted Dr. Rylander about working in his lab and have been involved with his 
research since. Working with  Drs. Rylander and Milner led me to the current project I have 
taken on.  
1.2   Research Inspiration 
 
 The research I am working on was inspired by the technology currently being optimized 
and utilized in the lab for imaging, namely Optical Coherence Tomography (OCT). The lab team 
had been investigating OCT as a potential imaging tool with which one could diagnose 
Alzheimer’s disease prior to my arrival. A key limitation the lab faces is obtaining accurate, 
reusable physical models of tissue that has undergone neuronal degradation and corresponding 
mitochondrial fission. Mice models have been used previously, but physical/experimental results 
need to be interpreted in the context of expected and controlled results.  
1.3   Research Target 
 
 The goal of my research was to create the “expected, controlled results” that might be used 
for benchmarking experimentally acquired results. The first component of my work was creating 
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a model with relevant physiological parameters that could predict how light would interact with a 
single sphere, utilizing Mie Theory (to be discussed). This could tell us how light interacts with 
an individual mitochondrion. The second component of my research was creating a Monte Carlo 
model that demonstrates the process of mitochondrial fission during Alzheimer’s disease, given 
certain inputs. The objective was to incorporate “memory” so that we could effectively model 
and track individual mitochondria in a person affected by the disease. Finally, the two models 
can be used together to demonstrate how overall mitochondrial morphology evolves during 
Alzheimer’s disease and how light interactions change in response.  
2   Significance and Description of the Problem 
 
2.1   The Prevalence of Alzheimer’s Disease 
 
 Today, Alzheimer’s disease affects approximately 24 million individuals and current 
estimates predict a quadrupling of this figure by 20501. Every 66 seconds someone in the United 
States develops Alzheimer’s. This high incidence rate means that approximately five million 
Americans are living with the disease, and that number is projected to grow to 16 million over 
the next 30 years. Alzheimer’s is a terminal illness and is the sixth leading cause of death in the 
United States2. The growth of these figures in the United States is in large part due to the aging 
of the massive “baby boom” generation3. In 2010 only 13% of the U.S. population was aged 65 
and over, but the “baby boom” generation is so large that the percentage of the population aged 
65 and over is expected to be over 20% in 20304.  
 Age is the best-known risk factor for Alzheimer’s disease, so an aging population is a 
strong cause for concern5. The impact on the overall health of the population is not the only 
problem that an aging population poses. The economic burden of the disease is equally troubling 
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and will only become more so as the prevalence increases. Alzheimer’s has been found to have 
higher health care costs than any other disease. In the last five years of life, total health care 
spending per afflicted patient averages over a quarter million dollars. This cost is 57% greater 
than other diseases, including cancer and heart disease6. This year, in the United States alone, 
Alzheimer’s and other forms of dementia will cost the nation 259 billion dollars. Medicaid and 
Medicare will cover approximately $175 billion, or 67 percent, of this figure. By 2050, these 
costs could rise to 1.1 trillion, which translates to a fourfold increase in government spending 
related to the disease2.  
2.2   The Prognosis of Alzheimer’s Disease 
 
 According to the Alzheimer’s Association, Alzheimer’s disease can generally be described 
as having three broad stages: mild (early-stage), moderate (middle-stage) and severe (late-stage). 
Symptomatic determination of a particular disease phase is challenging because symptoms often 
overlap and are so variable between afflicted individuals. The disease is known to be terminal, 
but progresses at rates variable by person. The typical life expectancy upon diagnosis is six to 
eight years, but some individuals have been known to live twenty years after diagnosis. Thus, life 
expectancy is quite difficult to determine upon initial diagnosis and most often is projected based 
on the severity of symptoms and the rate at which they are progressing over time within the 
specific patient7. 
 An unofficial stage of the disease exists known as the preclinical phase. In this phase, 
degenerative changes in the brain, like those to be discussed in the next section, are occurring but 
symptoms have not yet started to present themselves. These degenerative changes in the brain 
can begin up to a decade prior to the appearance of symptoms8.  
 The first stage of Alzheimer’s disease is known as mild Alzheimer’s or the early-stage. In 
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this stage, cognition and memory are primarily affected but the afflicted individual is often able 
to continue with daily work and social activities. Often times, individuals in this stage face 
problems determining the right word for certain objects. They might also struggle with locating 
everyday objects. They will often forget the names of new people and can have difficulty 
concentrating, planning and organizing7. Family members and close friends often become aware 
of these changes. But, these symptoms might be overlooked, as common forgetfulness amongst 
the elderly is the accepted social norm9. This is especially problematic because a late diagnosis 
might be detrimental.    
 The second stage of Alzheimer’s disease is moderate Alzheimer’s or the middle-stage. The 
middle-stage is generally the longest of the three phases and can last many years. Over the 
course of this stage, the patient will become increasingly dependent on a caregiver. The cognitive 
decline in the middle-stage is much greater than in the early-stage. Individuals will begin to 
forget important details about family members and friends, including names and faces. They also 
begin to forget details of their own personal history. They have trouble remembering important 
details like their phone number or addresses, which is dangerous because there is also an 
increased risk of wandering or getting lost. They begin to require help with daily tasks like 
getting dressed for appropriate weather conditions. Physical symptoms may also present 
themselves. For instance, some individuals with moderate Alzheimer’s notice changes in sleep 
patterns and some become incontinent7.  
 The final stage of Alzheimer’s disease is known as severe Alzheimer’s or the late-stage. 
This stage is characterized by acute, critical physical changes. Individuals in this stage will 
experience difficulty walking, sitting and eventually swallowing. Memory and cognition are 
affected greatly and significant personality changes result. Patients will need constant medical 
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supervision and care during this stage. Additionally, late-stage individuals become more 
susceptible to infections, especially pneumonia7. One study found that approximately 40% of 
late-stage Alzheimer’s patients die as a result of infection, specifically bronchopneumonia10. 
Near the end of this phase, the patient will most likely be bed-ridden while the body shuts down8.  
2.3   The Physiology of Alzheimer’s Disease 
 
 The physiology and epidemiology of Alzheimer’s disease is quite complicated, which is 
why the task of diagnosis is such a challenging one. Examination of brain tissue post-mortem 
under a microscope, during a procedure like an autopsy, can allow us to look for the two 
physiological hallmarks of the disease, namely neurofibrillary tangles and amyloid plaques. 
Neurofibrillary tangles are essentially bundles of fibers that consist of tau protein. Amyloid 
plaques appear like clumps, and consist of beta-amyloid protein8. Figure 1 below depicts brain 
tissue in healthy individuals and in Alzheimer’s patients after the development of neurofibrillary 
tangles and amyloid plaques11.  
 Neurofibrillary tangles almost always exist in Alzheimer’s patients. The number of 
neurofibrillary tangles is closely tied to the level of disease progression, with a higher number of 
tangles corresponding to a more advanced disease state. This trend implies a correlation between 
the formation of neurofibrillary tangles and neuronal dysfunction. As stated previously, the 
Figure 1: Healthy (left) vs. Alzheimer's Disease (right) Brain Tissue 
Source:  BrightFocus Foundation 
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tangles consist of tau protein. But, the tau protein involved is unique in that it is highly 
phosphorylated. The presence of phosphorylated tau protein and corresponding neurofibrillary 
tangles is associated with problems in the microtubule networks of neurons. Specifically, there 
are key disturbances in the microtubular network that in turn produce disruptions in axoplasmic 
transport, the necessary movement of cellular components within a neuron12.  
 The general term amyloid refers to the protein fragments that the body naturally produces. 
But, beta-amyloid refers to a protein fragment “snipped” from an amyloid precursor protein 
(APP). In a healthy person, these fragments are degraded and removed. In patients with 
Alzheimer’s disease or other forms of dementia, these fragments coalesce to form hard, insoluble 
plaques11. Unlike for neurofibrillary tangles, it was challenging for scientists to find a direct link 
or correlation between concentration of amyloid plaques and the level of disease progression. 
However, recent research indicates that amyloid plaque solubility is the correlated physiological 
factor13.  
 While neurofibrillary tangles and amyloid plaques are considered the physiological 
hallmarks of Alzheimer’s disease, recent research reveals a strong connection between altered 
brain energetics and metabolism with the disease. Specifically, significant hypometabolism, a 
term meaning abnormally low metabolic rates, has been detected early in Alzheimer’s patients 
via 18F-fluorodeoxyglucose positron emission tomography (F-PET) scans. This suggests that 
abnormal energy metabolism underlies the development and progression of the disease14.  
 Neurons require robust energy production to maintain normal synaptic activity, to remain 
healthy and to survive. It is well known that mitochondria are the “powerhouse” of the cell. 
Thus, by definition, it is mitochondria that are responsible for the robust energy production that 
allows neurons to behave normally and survive. Mitochondria have to perform very specific 
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tasks in order to maintain an adequate amount of energy production. Recent studies reveal that 
one of these tasks mitochondria must perform is undergoing constant cycles of fission and 
fusion, collectively termed “mitochondrial dynamics”15–17.  
 The cellular machinery involved in performing the processes related to mitochondrial 
dynamics is very sensitive and depends on the fidelity of various proteins. Proteins that have 
been identified that influence mitochondrial dynamics include: dynamin related protein 1 (Drp1), 
mitochondrial fission protein 1 (Fis1), mitochondrial fission factor (Mff), mitofusin-1 and 
mitofusin-2 (Mfn1, Mfn2), and optical atrophy 1 (Opa1) protein. Levels of the aforementioned 
proteins affect how overall mitochondrial morphology shifts in response to the energetic 
demands of the cell by dictating whether fission or fusion will occur15,18–22.  
 Fission and fusion normally occur together in a balanced fashion with fusion being more 
common than fission. But, excessive fission has been observed in cellular and animal models of 
Alzheimer’s disease as well as in afflicted patients23. Normally, mitochondrial fission is a 
process that is essential for quality control ensuring that damaged or old organelles can be 
removed via mitophagy,15 a process that involves the engulfment of mitochondria by a 
phagophore and subsequent degradation to allow for a “recycling” of organellar parts24. 
Moreover, this fission process results in the consolidation of the “still-intact functional elements 
of mitochondria,” while simultaneously segregating dysfunctional mitochondrial components 
into “depolarized daughter organelles that are targeted for mitophagy”25. While mitochondrial 
fission enables quality control, mitochondrial fusion preserves mitochondrial function and 
subsequent cell energy production. Contemporary research indicates that a highly fused 
arrangement of mitochondria is a cellular response to energy deprivation and stressful 
environmental conditions26. This fused arrangement provides stress resistance and prevents 
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mitophagy27,28. So, it seems fusion prevents mitophagy while fission enables it. This idea offers 
an explanation for the balance of fission and fusion normally observed, where higher rates of 
fusion exist. Because mitochondria can have satisfactory life cycles, they need not be degraded 
as often as they need be preserved29.  
 The relationship between mitochondrial dynamics and the onset of Alzheimer’s disease is 
still being studied extensively. A recent study suggests that Alzheimer’s disease may be 
primarily a vascular disease where brain amyloid deposition is correlated with midlife vascular 
risk factors like high Body Mass Index (BMI), hypertension and diabetes. The study supposes 
that vascular problems create hypoxic stress in the brain, which then induces the aforementioned 
changes in mitochondrial dynamics. This altered balance leads to neuronal energy deficiencies 
and subsequent cell death30 
 Figure 2 below depicts three common mitochondrial morphologies found in a study by 
Zhang et al, where arrows indicate mitochondria. Each of the images was visualized using 
standard TEM and super-resolution immunofluorescence29. Image A corresponds to the 
prevalent mitochondrial structure in healthy individuals. Images B and C represent the two most 
common morphologies present during Alzheimer’s.  
Figure 2: Images of Mitochondrial Morphologies Found in Healthy Individuals (A) 
and Individuals with Alzheimer's Disease (B/C);  Source: Zhang et al. 
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Image A shows the more common, fused state that is prevalent in healthy individuals. Image B 
shows severely disjointed mitochondria, as would exist during Alzheimer’s disease when net 
fission is occurring. The Zhang et al study argues that the morphology shown in Image C is a 
precursor to the morphology present in Image B, and that it is the cell’s final attempt to preserve 
its energy production by having loosely connected mitochondria that are less susceptible to 
mitophagy29.  
 Furthermore, it appears that states of mitochondrial fission and fusion are both physically 
adaptive and required, especially in situations of metabolic stress or energy deprivation. But, it is 
clear that issues arise when more mitochondria are in a state of fission than fusion, as is the case 
with Alzheimer’s disease. The largest issue is that a higher proportion of mitochondria in a state 
of fission translates to excessive rates of mitophagy. This increased rate of mitophagy in turn 
creates a higher proportion of degraded, non-functional mitochondria and a corresponding 
inadequate number of intact, functioning mitochondria. Fewer functioning mitochondria means 
decreased energy production. Insufficient energy production leads to loss of synaptic activity and 
neuronal death, two conditions involved in the onset and progression of Alzheimer’s disease29.  
2.4   Current Diagnostic Techniques/Treatments for Alzheimer’s Disease 
 
 There are two potential preliminary diagnoses that can be made if a patient seeks medical 
attention for symptoms like memory problems. These are “possible Alzheimer’s dementia” and 
“probable Alzheimer’s dementia.” Possible Alzheimer’s dementia differs from probable 
Alzheimer’s dementia in that the dementia “might be due to other causes,” where in the case of 
probable Alzheimer’s dementia “no other cause for dementia can be found”8. 
 The diagnostic technique for Alzheimer’s disease is rather crude and almost subjective in a 
sense. Physicians will perform an array of tests and analyses to determine if someone has 
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probable or possible Alzheimer’s. First, the physician will investigate the patient’s overall 
medical history and will inquire about any recently observed changes in behavior, memory or 
personality with the patient and, if possible, the patient’s family and friends. Next, the physician 
may conduct some cognitive testing, like tests of memory, problem solving, language and 
attention. After that, the physician will carry out standard medical tests like urine and blood 
sampling. If necessary, the physician might also perform various types of brain scans (CT, PET, 
MRI, etc). The latter two testing procedures are completed to rule out any other potential causes 
for the disease, like vascular dementia8.  
  All of this testing leaves the patient with only one type of conclusion – an uncertain one. 
The uncertainty rests in the inability of current diagnostic techniques to definitively ascertain 
whether or not a patient is affected by Alzheimers. Unfortunately, the only time we can 
accurately and definitively diagnose a patient with Alzheimer’s is post-mortem, during an 
autopsy, when clinical measures can be linked with an examination of brain tissue under a 
microscope.  
 Currently, no cure for Alzheimer’s disease is available. However, some current medical 
technologies and practices are being used to preserve mental function, manage symptoms and 
potentially slow or delay the onset of symptoms while the disease progresses. A few medications 
have been approved by the FDA for use in human patients afflicted by Alzheimer’s. Medications 
that have shown efficacy in treating mild to moderate Alzheimer’s include: donepezil, 
rivastigmine, and galantamine. Effective medications for moderate to severe Alzheimer’s include 
donepezil and memantine. All of the previously listed drugs work by modulating 
neurotransmitters. While these medications have been shown to be effective in reducing 
symptoms they do not change the underlying disease pathology. Additionally, they are not 
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effective for all patients and may help some patients for only a limited time8.  
2.5   Future of Diagnostic Techniques and Benefits of Early Diagnosis 
 
 Scientists around the world are investigating various novel diagnostic techniques and 
strategies. Some diagnostic techniques being studied that have shown promise in diagnosing 
Alzheimer’s early include: cerebrospinal fluid (CSF) protein testing, functional imaging and 
molecular imaging. Each technique varies in its approach and has specific drawbacks31.  
 Testing of cerebrospinal fluid (CSF) proteins appears promising. This procedure involves a 
sampling of CSF via a lumbar puncture. The levels of certain proteins, specifically tau and beta-
amyloid, are then examined in that CSF sample. Because research suggests that these proteins 
accumulate and are prevalent in the earlier stages of Alzheimer’s, these levels could help 
physicians determine if a patient is developing Alzheimer’s31. However, two key issues are 
associated with this technique. The first is the invasiveness of the procedure. Most patients do 
not seek medical attention until symptoms appear, and those that do will likely be averse to a 
diagnostic lumbar puncture. This makes detection at the earliest stages, before severe and 
irreversible damage to the brain occurs, less likely. The second limitation is that “analysis of 
protein levels in the same sample often varies significantly from institution to institution”31. 
Thus, achieving consistent measurement and analysis to have meaningful results remains a 
challenge.  
 Functional imaging is also being explored as a potential diagnostic tool. As mentioned 
previously, alterations in brain metabolism and activity have been observed in patients with 
Alzheimer’s. One study using F-PET imaging showed that Alzheimer's disease is often 
associated with hypometabolic activity (reduced use of glucose) in brain areas involved in 
memory, learning and problem solving14. So, functional imaging could be used to detect changes 
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in brain metabolism, which starts to occurs in the earliest stages (preclinical) of Alzheimer’s. 
However, this technique has one key limitation, namely the lack of confirmed information 
needed for scientists to draw connections between the observed activity patterns and diagnostic 
information31. 
 Another imaging technique, molecular imaging, is also being investigated as a diagnostic 
tool. This technique has the potential to diagnose Alzheimer’s before the disease permanently 
alters a patient’s brain structure or function. Molecular imaging relies on molecular markers that 
adhere to relevant pathological molecules, proteins or tissues. For instance, one specific 
radiotracer, known as Pittsburgh compound B (PIB), is capable of highlighting beta-amyloid 
deposits. This technique is minimally invasive, but is limited by the pace of molecular marker 
discovery. Also, those molecular markers that do exist might not be entirely useful for diagnostic 
purposes. For instance, beta-amyloid concentration is not directly correlated with a level of 
disease progression, so the benefit of marking that specific protein is limited31.  
 The race to discover an accurate technique or effective tool that can diagnose Alzheimer’s 
at its earliest stages is very important. There are a multitude of benefits that can be derived from 
an early diagnosis. Firstly, the patient is afforded earlier access to available treatments, is able to 
build a care team, can investigate support services and enroll in potentially effective clinical 
trials. Aside from the physical benefits, early-diagnosed patients can better prepare emotionally, 
socially, financially and legally for the toll the disease takes on the body and mind32.  
 Approximately 89% of Americans say they would want to know if they had Alzheimer’s if 
they were experiencing confusion or memory loss, but less than half of Americans living with 
Alzheimer’s are aware they have the disease32. So, it is clear that our current diagnostic 
techniques fall short and that a more effective diagnostic tool would be well received.  
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3   Approach to Diagnosis via Optical Coherence Tomography  
 
3.1   Optical Coherence Tomography as an Imaging Technique 
 
 Optical Coherence Tomography (OCT) is a relatively new imaging technique that allows 
for high-resolution, cross-sectional imaging. OCT is similar to ultrasound in function, but utilizes 
light instead of sound to generate images. OCT has been shown to be useful in imaging 
microstructures present in biologic systems, and operates by measuring backscattered light. The 
images produced by OCT systems are essentially “two-dimensional data sets, which represent 
optical backscattering in a cross-sectional plane of tissue”33.  
 There are many advantages to using OCT as an imaging technique. Image resolutions of 1 
to 15 µm can be achieved, which is one to two orders of magnitude higher than typical 
ultrasound technology. In addition, imaging can be performed in situ and in real time. The ability 
to image tissue in situ and in real time means that OCT can serve as a sort of optical biopsy. The 
traditional method of determining tissue changes that result from disease is the removal of tissue 
and subsequent microscopic examination. So, for the aforementioned reasons, OCT might be a 
good substitute for excisional biopsies in cases where tissue excision is dangerous or impossible. 
In addition, OCT imaging can reduce the sampling errors associated with excisional biopsies33. 
 The first applications of OCT imaging were in the field of ophthalmology. OCT is 
Figure 3: Visualization of retinal layers, imaged by Swept-Source OCT (SS-OCT); Source: Optician 
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especially useful in this field because the technology enables noncontact, noninvasive imaging of 
the anterior eye and of morphologic features of the human retina. Figure 3 above is an OCT scan 
of a human retina. The image reveals the high resolution OCT imaging can provide and how 
detailed microstructures can be differentiated34. Optical imaging of the retina at this level is 
normally very difficult because of the retina’s transparency and extremely low levels of optical 
backscattering. However, OCT imaging is highly sensitive and allows these poor backscattering 
features to be visualized. 
 In all, there are several key biomedical applications of OCT. The first has already been 
noted, which is the ability of OCT to image at high resolutions revealing morphology and 
allowing some cellular features to be resolved. Second, OCT can image directly through the air 
without needing to make contact with the tissue of interest, representing a key advantage over 
ultrasound. Because OCT can image in situ, sampling errors can be reduced due to enhanced 
coverage. Additionally, real-time imaging provides real-time diagnostic potential. 
3.2   Mitochondrial Imaging via Optical Coherence Tomography 
 
  Our lab is investigating OCT as a tool by which to early diagnose Alzheimer’s. This 
would involve observing the aforementioned morphological changes of mitochondria that occur 
because of the disease. Detecting mitochondrial structure in vivo is a unique challenge, because 
of the small size of mitochondria, which have diameters of approximately 0.75 µm35. This 
particle size is beyond the resolution of most imaging techniques. However, mitochondria have 
interesting properties that make them appealing candidates for optical imaging. Specifically, 
mitochondria have distinctive light scattering characteristics. Imaging mitochondria specifically 
in the retina is even more useful in the context of diagnosing Alzheimer’s because of the 
relationship between the brain and the optic nerve. We know that the optic nerve is 
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embryonically derived from the forebrain and also enclosed by the meninges, the three 
membranes that envelop the brain and spinal cord. For these reasons, many scientists 
increasingly view the eye as the “window to the brain”36,37. In addition, recent research suggests 
that retinal changes occur alongside brain changes during neurodegenerative disease, like 
Alzheimer’s36,38–40. Furthermore, OCT imaging would be a useful tool to monitor changes in 
mitochondrial dynamics occurring in “brain tissue” during Alzheimer’s, since the technique is 
already widely used to image the retina and because the retina is closely related to the brain. 
However, standard OCT systems are unable to image mitochondrial morphology with sufficient 
resolution.  
 A previous study conducted in the lab I have been working in, the Biomedical Engineering 
Laser Laboratory (BELL), at the University of Texas at Austin attempts to resolve this issue of 
resolution. The study involved optimizing the design and construction of a scattering-angle 
resolved OCT system (SAR-OCT) to better investigate the optical properties of healthy human 
retinas41. The study concluded that ocular regions with “lower retinal ganglion cell density” were 
correlated with the SAR-index. Further, the lab has demonstrated that sub-resolution light 
scattering variations in the retina can be detected. This means that the lab has the potential, using 
SAR-OCT, to observe the sub-resolution light-scattering variations that are a product of 
mitochondrial structural changes during neurodegenerative diseases like Alzheimer’s.  
3.3   Split-Spectrum SAR-OCT  
 
 Split-spectrum (SS) SAR-OCT is an imaging process technique that can be utilized to 
derive information about how scattering properties of light are influenced by the size of 
scatterers in a medium. In terms of our research, SS-SAR-OCT could be useful in determining 
the size of mitochondria (the scatterer) in the retina (the medium). SS-SAR-OCT would involve 
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probing the retinal sample at different wavelengths to identify the wavelength dependence of the 
dispersed scatterers, which in my study are mitochondria. According to Mie Theory, the 
scattering profile of light around a spherical object that has a size close to the incident light’s 
wavelength will be wavelength-dependent. This means that a new SAR index (SARi) could be 
calculated for various spectra. Taking the mean of the second derivative of the SARi (SARi’’) 
would then allow us acquire information about the concavity, or curve directionality, of the 
scatterer’s dependence on wavelength. This is possible because a second derivative of a function 
indicates its concavity. Further, we could use SARi’’ to map a trend that would help in observing 
the relevant sub-resolution light-scattering variations, which could potentially point to 
mitochondrial structure and help us relate that structure to a relevant disease state.  
4   Monte Carlo Modeling of Mitochondrial Fission 
 
4.1   Monte Carlo Model Relating Mitochondrial Structure and Scattering 
Profiles 
 
 My individual research had two major components. The first was building a Monte Carlo 
model that simulates mitochondrial morphological changes as they occur during Alzheimer’s 
disease. The second component involved creating a computer program that predicted light 
scattering profiles of a sphere according the Mie Theory.   
4.1.1    Monte Carlo Model 
 
 My early research suggested that no complex computational models existed that accounted 
for changing mitochondrial dynamics during neurodegenerative diseases. There have been 
images generated computationally that depict mitochondrial morphology in states of fission and 
fusion, respectively29,42. But, none of these images incorporated “memory.” By that I mean there 
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were no models that generated a set of mitochondrial chains and then manipulated those specific 
chains to simulate how a neurodegenerative disease would progress over time. So, I set out to 
create a Monte Carlo model that forecasted changes that occur to overall mitochondrial 
morphology as a result of Alzheimer’s.  
 Monte Carlo simulations are useful in their own right because they allow a user to input 
certain parameters and then output probable outcomes according to those parameters. To build a 
Monte Carlo simulation for changing mitochondrial dynamics, I did a literature search to get a 
better understanding of what happens to mitochondria during neurodegenerative diseases like 
Alzheimer’s. It became clear that fission and fusion occur together and randomly, with more 
fission events occurring during Alzheimer’s than in normal tissue23,29,43. In addition to separating 
from one another, mitochondria also experience a decrease in diameter and an increase in index 
of refraction (IOR) when fission occurs. In a fused state, mitochondria are elongated and share a 
membrane, and as a result have a larger diameter. A larger size translates to less densely packed 
mitochondria, producing the lower index of refraction observed in fused mitochondria relative to 
isolated mitochondria29,44,45. Various authors report slightly different diameters for mitochondria 
that are fused, but all fall around a 0.75 µm figure. The shrinking of the mitochondria in response 
to fission processes results in a new average diameter of approximately 0.4 µm22,29,46,47. 
Simultaneously, the IOR of a mitochondrion changes from approximately 1.37 to 1.41 as fission 
occurs and organelles becomes isolated29,44,45. The average distance between mitochondria that 
have undergone fission was estimated to be approximately 3 µm via inspection of images 
produced in various studies, like those conducted by Zhang et al shown in Figure 229,42.   
 Utilizing the aforementioned data in MATLAB, I randomly generate a specified number of 
mitochondrial chains (a user input) containing a variable number of mitochondria (uniform 
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distribution about a mean of 6 mitochondria per chain29,42) in a 50x50x50 volume, representing a 
potential sample of imaged retinal tissue. The chains are built parallel to one another but 
distributed within the “tissue,” modeling the average observed orientation of mitochondrial 
chains in retinal cells, where the chains run along the same axis as the length of the cell body48. 
Each individual mitochondrion is assigned a diameter that is normally distributed about the 
average diameter observed in fused states of 0.75 µm (σ = 0.05 µm). Additionally, each 
mitochondrion is randomly assigned an index of refraction normally distributed about 1.37 (σ = 
0.01 µm), the average IOR observed in fused mitochondria. The randomly generated 3-
dimensional coordinates for each mitochondrion are stored. There is a minimum distance 
between mitochondrial chains imposed that constrains the number of chains that can be “built” in 
the given volume. This distance was roughly assigned and is related to the diameter of the largest 
mitochondrion.  
 The user then inputs a desired number of “frames” that will dictate the number of steps that 
are taken towards a state of complete fission. For instance, if the user inputs a value of 100 for 
“frames” there will be 100 images generated, where each subsequent image represents an 
additional 1% movement towards fission. Using vector calculations, the model estimates the 
“shape” or “linearity” of each mitochondrial chain. Adding some variability to this shape with 
each step, but maintaining an overall linear directionality, new coordinates are calculated for 
each mitochondrion in each frame. Along with a physical movement within the model volume 
comes a change in the diameter and IOR for each mitochondrion, depending upon the diameter 
and IOR of the previous frame, and trending towards the values of diameter and IOR noted in 
fully isolated mitochondria. This is how “memory” is incorporated in the model.  
 The mitochondria are modeled as spheres. The color of each sphere, or mitochondrion, is 
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mapped to its respective index of refraction. Lower and higher indices of refraction correspond 
to blue and green, respectively. So, the lower the IOR the bluer the sphere appears, or the higher 
the IOR the greener the sphere appears. The relative diameters can also be observed in each 
frame. 
 See Appendix A for the relevant code. 
4.1.2    Light Scattering Profile Generator 
 
 At this point, the second component of my research became relevant. Prior to building the 
Monte Carlo model, I built a MATLAB program that could output light scattering profiles when 
passed specific parameters regarding a spherical scatterer and the medium through which the 
light travels. As mentioned previously, Mie Theory describes and defines the way that spheres 
scatter light in a medium. Because the mitochondria may be in a fusion state, simulating light 
scattering by a single sphere is an approximation and does not account for interactions between 
neighboring mitochondria.  Parameters affecting light scattering profiles when light interacts 
with dispersed spherical scatterers are: wavelength of incident light, diameter of scatterer, IOR of 
the medium, IOR of the scatterer, concentration of the scatterers within the medium and the 
number of angles49. These parameters were made inputs to my program.  
 Consider a point light source, a spherical scattering particle, and an observer whose three 
positions define a plane called the scattering plane. Incident and scattered light can be reduced to 
their components that are parallel and perpendicular to the defined scattering plane. If you 
average these two components for scattered light, you produce natural values that correspond to 
the relative intensity of scattered light at each angle49. These natural values can be mapped on a 
polar plot to produce a light scattering profile. If you plot the radial distance values 
corresponding to relative intensity on a log scale you can generate a slightly different polar plot 
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that allows for a better visualization of side lobes in the scattering profile.  
 The Oregon Medical Laser Center previously created a Mie Scattering Calculator that 
allows you to input the mentioned parameters50. The limitation of this online calculator is that 
you have to change parameters and generate data/scattering profiles one by one. In order to solve 
this problem, I utilized the code they provided on their website for the calculator and optimized it 
to function as a program in MATLAB that receives the parameters in sets. The code I optimized 
and created calculates the natural values and maps the corresponding light scattering profiles on 
a log scale. See Appendix A for the relevant code.  
4.1.2    Intersection of Monte Carlo Model and Scattering Profile Generator 
 
 After completing both sets of code, I wanted to combine the two. My final model generates 
two separate plots and shows them in the same figure. The first plot is a specific frame of the 
Monte Carlo model, showing the overall morphology of the independent mitochondrial chains. 
The second plot is a scattering profile. The scattering profile generated is related to each frame of 
the Monte Carlo model. I randomly select one mitochondrion from the set of mitochondria in the 
model and track that specific mitochondrion’s changes in IOR and diameter over time. I pass that 
data to the scattering profile generator in each frame and subsequently create a scattering profile. 
Note that the modeled light is incident from the left. 
 This combination is useful because it allows us to view and record the simulated changes 
in overall mitochondrial structure during the progression of Alzheimer’s disease. At the same 
time, we can see how light would scatter upon interaction with a specific mitochondrion, relating 
changes in light scattering with changes in mitochondrial structure due to the disease.  
4.2   Results 
 
 The final product of my model is a movie that simulates the progression of the disease. The 
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user inputs the number of frames desired, as well as a value for frames per second that 
determines the length of the film.  
 Below are screenshots of a film showing 50 mitochondrial chains undergoing the fission 
processes associated with Alzheimer’s. Parameters passed to the scattering profile generator to 
produce the right side of each figure were: the randomly selected mitochondrion’s diameter, 
incident light wavelength of 1050 nm (an OCT relevant wavelength), IOR of medium equal to 1, 
IOR of randomly selected sphere, angles value of 360 and a concentration of 0.1.  
 Figure 4 represents steady state, or fusion in the tissue. This would resemble a 
mitochondrial structure and scattering in a healthy individual. 25%, 50%, 75% and 100% 
progression towards fission are depicted by figures 5, 6, 7 and 8, respectively.  
Figure 4: Screenshot from Output of Monte Carlo Model at Steady-State (Progression to Fission = 0%) 
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Figure 5: Screenshot from Output of Monte Carlo Model (Progression to Fission = 25%) 
Figure 6: Screenshot from Output of Monte Carlo Model (Progression to Fission = 50%) 
Figure 7: Screenshot from Output of Monte Carlo Model (Progression to Fission = 75%) 
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I have posted the video corresponding to these screenshots on YouTube. The link is as follows: 
https://youtu.be/W5CmLAasqqM. The video can also be searched for by typing in the following 
title: “Modeling Mitochondrial Fission During Alzheimer's Disease.”  
 The left-hand side of each of these figures models closely the structural changes that occur 
to mitochondria during the fission processes associated with Alzheimer’s disease. 
Simultaneously, the right-hand side shows how the light scattering profiles are affected by these 
changes. There appears to be a more even distribution of scattering when the scatterer, or 
mitochondrion, undergoes a decrease in diameter and increase in IOR. This confirms the idea 
that the backscattered light distribution changes with changes in scatterer properties.  
 The lab’s hypothesis is that mitochondrial fission will result in a relative increase in large 
angle backscattered light compared to low angle light.  The results from this model are consistent 
and support this hypothesis.  However, a limitation of the model is that we are currently only 
able to predict light scattering from a single mitochondrion and not include effects from 
interacting units. 
Figure 8: Screenshot from Output of Monte Carlo Model (Progression to Fission = 100%) 
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4   Conclusion and Future Work 
 
4.1   Concluding Remarks 
 
 This model is unique in its ability to predict and simulate physiological changes that are 
known to occur in the retina during neurodegenerative diseases like Alzheimer’s. It is also useful 
in that it allows us to create a rudimentary prediction of how light would interact with a specific 
mitochondrion within a sample that is being imaged. Further, the model provides us with a better 
understanding of what to expect from optical imaging of the retina during a disease like 
Alzheimer’s. 
 The future development and application of this model has the potential to provide the 
“controlled, expected results” we might want to compare with those we experimentally acquire 
in lab, using a murine model. In addition, having a computational model that can predict how the 
OCT signal would vary with disease state is a more ethical first step than using an animal model 
to gather the same data. 
4.1   Future Work 
 
 This model and its applications still stand to be developed further. Namely, we might be 
able to use it in the future to identify the wavelength-dependence of the scatterers in the model 
“volume.” This would allow us to generate SARi and SARi”” data, which could be used to map 
trends that would help us identify the relevant sub-resolution light-scattering variations that are 
occurring during Alzheimer’s. For instance, we could potentially create a lookup table where the 
axes are SARi and SARi’’. The intersection of various combinations of SARi and SARi’’ could 
contain information about mitochondrial size/structure. This information about mitochondrial 
structure could help us identify a relevant disease state. We could also experimentally confirm 
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this table and this model by building phantoms with a medium in which scatterers are dispersed. 
 If this does become possible and we ultimately predict light scattering from multiple 
interacting scatterers as opposed to non-interacting units, we would have a more robust model 
with many more clinical applications. We could create a similar lookup table that would serve as 
a heuristic by which an earlier stage diagnosis could be made. This diagnosis would be earlier 
than current methods allow for because variations in mitochondrial dynamics occur in the 
earliest stages of the disease (preclinical). Additionally, this technique would be non-invasive 
and therefore has the potential to become a part of a standard check-up in at risk patient 
populations. 
 In order to make the model more robust, further literature review should be conducted as 
more information regarding the relationship between mitochondrial morphology and 
Alzheimer’s comes to light. This would allow for the integration of more parameters that would 
make the model more accurate in simulating the changes that occur in vivo. The code I have 
written can also be improved by adding any additional complexity the next user sees fit.  
 In all, the future of this “workstream” is bright and is meant to be continued by other 
investigators.  
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Appendix A: MATLAB code 
 
1) chain_maker_final.m 
The main code that calls the other necessary functions  
 
%% clear/initialize workspace 
clc; 
clear all; 
  
chainnum = 50; 
lowerbnd = 5;                  %variables to be passed to centerpoints.m 
  
                    %parameters passed to scattering profile generator 
lambda = 1050;      %wavelength of incident light (OCT relevant); units=nm 
nmed = 1;           %IOR of medium 
angles = 360;    
conc = .1;          %scatterer concentration 
  
%% we first need to decide how many mitochondria are within each chain 
%  and determine the average chain length 
  
  
for i=1:chainnum 
    avg_num = normrnd(6,1); %avg number of mito in chain is ~6 
                             % see bioenergetics paper 
    mito_num = round(avg_num);  %needs to be discrete 
    chain_nums(i,1) = mito_num; 
end 
  
  
% create data for individual mitochondria  
% each row corresponds in this matrix is a single chain's mito's 
for j=1:length(chain_nums) 
for i=1:chain_nums(j,1) 
    mito_diams(j,i) = normrnd(.75,.05);     %diameters for each mito w/in 
chains 
    mito_ior(j,i) = normrnd(1.37,.01);        %index of refraction for each 
mito w/in chains 
                                            %high end of overall cell.. 
                                            %approaches 1.41 when isolated 
end 
end 
   
maxd = max(max(mito_diams)); 
maxl = max(sum(mito_diams')); 
%% variability in the z direction (state=0) 
%  will depend on the imported centerpoints from centerpoints code 
  
centers = centerpoints(chainnum, lowerbnd, maxd, maxl); 
bottom = centers(:,3) - lowerbnd; 
z(:,1) = bottom + 1/2*mito_diams(:,1);      %find the z of centerpoint for 
1st mito 
for i=2:max(chain_nums) 
    z(:,i) = z(:,i-1) + 1/2*mito_diams(:,i-1) + 1/2*mito_diams(:,i); %create 
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next z  
end 
diam_zeros = find(mito_diams==0); 
for i=1:length(diam_zeros) 
    element = diam_zeros(i); 
    z([element]) = 0; 
end 
  
%% variability in the x direction 
x(:,1) = centers(:,1); 
for i=2:max(chain_nums) 
    x(:,i) = normrnd(x(:,i-1),1/250*x(:,1)); 
end 
for i=1:length(diam_zeros) 
    element = diam_zeros(i); 
    x([element]) = 0; 
end 
  
%% variability in the y direction 
y(:,1) = centers(:,2); 
for i=2:max(chain_nums) 
    y(:,i) = normrnd(y(:,i-1),1/250*y(:,1)); 
end 
for i=1:length(diam_zeros) 
    element = diam_zeros(i); 
    y([element]) = 0; 
end 
%% fission processes INPUTS!! 
maxf = 3;     %max fission distance (um) for disjointed mitos 
frames = 40;  
t = .1; 
  
  
%% individual mitochondria data pull 
test_mito=zeros(frames+1,2); 
test_mito(1,1)=mito_diams(1,1); 
test_mito(1,2)=mito_ior(1,1); 
  
%% plot specific spheres for t=0 
[a,b,c] = sphere; 
subplot(1,2,1); 
for i=1:size(x,1) 
for j=1:size(x,2) 
    if x(i,j)~=0&&y(i,j)~=0&&z(i,j)~=0 
        xx = a/2*mito_diams(i,j)+x(i,j); %scaled/translated x 
        yy = b/2*mito_diams(i,j)+y(i,j); %scaled/translated y 
        zz = c/2*mito_diams(i,j)+z(i,j); %scaled/translated z 
        col = ones(size(zz))*(mito_ior(i,j)/1.42); 
        surf(xx,yy,zz,col,'edgecolor','none'); 
        hold on 
    end 
end 
end 
  
  
grid on; 
xlabel('x'); 
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ylabel('y'); 
zlabel('z'); 
title('Progression to Fission: 0%'); 
view(3); 
colormap winter 
camlight 
axis([0 50 0 50 0 50]) 
subplot(1,2,2); 
  
% User Inputs to Mie Theory 
natural = mie_scatter(test_mito(1,1), lambda, nmed, test_mito(1,2), angles, 
conc); 
  
nat = natural(2,:); 
lognat = log(nat); 
polarplot(-(lognat+10)) 
rlim([0 12]); 
ax = gca; 
d = ax.ThetaDir 
ax.ThetaDir = 'clockwise'; 
ax.RTick = [0 5 10]; 
ax.RTickLabel = {' ',' ',' '}; 
  
  
set(gcf, 'Units','pixels','Position',[0 0 1280 640]) 
  
F(1) = getframe(gcf); 
close all; 
  
%% plot specific spheres during f 
close all; 
  
%% plot specific spheres during fission 
[a,b,c] = sphere; 
t_frame = 1/(frames); 
for k=1:frames 
ission 
[a,b,c] = sphere; 
t_frame = 1/(frames); 
for k=1:frames 
[x,y,z,mito_ior,mito_diams] = 
fission(x,y,z,maxf,frames,mito_ior,mito_diams,chain_nums,t); 
t_frame_k(k) = t_frame*k*100; 
figure; 
subplot(1,2,1); 
for i=1:size(x,1) 
for j=1:size(x,2) 
    if x(i,j)~=0&&y(i,j)~=0&&z(i,j)~=0 
        xx = a/2*mito_diams(i,j)+x(i,j); %scaled/translated x 
        yy = b/2*mito_diams(i,j)+y(i,j); %scaled/translated y 
        zz = c/2*mito_diams(i,j)+z(i,j); %scaled/translated z 
        col = ones(size(zz))*(mito_ior(i,j)/1.42); 
        surf(xx,yy,zz,col,'edgecolor','none'); 
        hold on 
    end 
end 
end 
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grid on; 
xlabel('x'); 
ylabel('y'); 
zlabel('z'); 
view(3); 
str = sprintf('Progression to Fission = %1.0f%%',t_frame_k(k)); 
title(str); 
colormap winter 
camlight 
axis([0 50 0 50 0 50]) 
test_mito(k+1,1)=mito_diams(1,1); 
test_mito(k+1,2)=mito_ior(1,1); 
  
subplot(1,2,2); 
  
% User Inputs to Mie Theory 
natural = mie_scatter(test_mito(k+1,1), lambda, nmed, test_mito(k+1,2), 
angles, conc); 
nat = natural(2,:); 
lognat = log(nat); 
polarplot(-(lognat+10)) 
rlim([0 12]); %keeps scale of the polar plot consistent 
ax = gca; 
d = ax.ThetaDir 
ax.ThetaDir = 'clockwise'; 
ax.RTick = [0 5 10]; 
ax.RTickLabel = {' ',' ',' '}; 
  
  
set(gcf, 'Units','pixels','Position',[0 0 1280 640]) 
F(k+1) = getframe(gcf); 
close all; 
end 
  
  
%% make movie 
  
myVideo = VideoWriter('100mito40frames4fps.avi'); 
myVideo.FrameRate = 4; 
open(myVideo); 
writeVideo(myVideo, F); 
close(myVideo); 
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2) fission.m 
Called during chain_maker_final.m 
 
function [x,y,z,mito_ior,mito_diams] = 
fission(x,y,z,maxf,frames,mito_ior,mito_diams,chain_nums,varargin) 
%% vector calculation component 
for i=1:size(x,2)-1 
xii = x(:,i+1); 
xio = find(xii==0);     %find when an element is 0, bc no vector needed 
vx(:,i) = x(:,i+1) - x(:,i); 
vx(xio,i) = 0;          %replace incorrect vectors with 0 
vy(:,i) = y(:,i+1) - y(:,i); 
vy(xio,i) = 0; 
vz(:,i) = z(:,i+1) - z(:,i); 
vz(xio,i) = 0; 
end 
  
%% fission distance a function of t/number of frames 
inc_f = maxf/frames;        %incremental distance depending on frames 
  
f_scal = zeros(length(chain_nums),max(chain_nums)); 
for i=1:size(f_scal,2) 
    f_scal(:,i) = i; 
end 
f_scal = f_scal./chain_nums; 
  
% t=varargin{1}; 
% poi = t*maxf*frames;               %point of interest, if desired 
  
%% add variability 
var_f = inc_f*normrnd(1,maxf/20);   %add variability to incremental f 
var_vx = vx*normrnd(1,max(max(abs(vx)))/20); 
var_vy = vy*normrnd(1,max(max(abs(vy)))/20); 
var_vz = vz*normrnd(1,max(max(abs(vz)))/20); 
  
%% movement 
opt = randi(2,1); 
if opt == 1                 %leave bottom mito fixed 
    var_ff = var_f*f_scal; 
    var_ff = var_ff(:,2:size(x,2)); 
    %x 
    xk = x(:,1); 
    xx = x(:, 2:size(x,2)); 
    xx = var_vx.*var_ff/5+xx; 
    x = [xk,xx]; 
    %y 
    yk = y(:,1); 
    yy = y(:, 2:size(y,2)); 
    yy = var_vy.*var_ff/5+yy; 
    y = [yk,yy]; 
    %z 
    zk = z(:,1); 
    zz = z(:, 2:size(z,2)); 
    zz = var_vz.*var_ff+zz; 
    z = [zk,zz]; 
end 
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if opt == 2                 %leave top mito fixed 
    f_scal = flip(f_scal,2); 
    var_ff = var_f*f_scal; 
    var_ff = var_ff(:,1:size(x,2)-1); 
    %x 
    xk = x(:,size(x,2)); 
    xx = x(:, 1:size(x,2)-1); 
    var_vx = var_vx*-1; 
    xx = var_vx.*var_ff/5+xx; 
    x = [xx,xk]; 
    %y 
    yk = y(:,size(y,2)); 
    yy = y(:, 1:size(y,2)-1); 
    var_vy = var_vy*-1; 
    yy = var_vy.*var_ff/5+yy; 
    y = [yy,yk]; 
    %z 
    zk = z(:,size(z,2)); 
    zz = z(:, 1:size(z,2)-1); 
    var_vz = var_vz*-1; 
    zz = var_vz.*var_ff+zz; 
    z = [zz,zk]; 
end 
  
%% mitochondrial changes 
mito_mask = mito_ior; 
mito_mask(mito_mask>0) = 1; 
%Index of Refraction changes to become higher when isolated 
IR_column = 1.37; 
IR_isolated = 1.41; 
deltaIR = IR_isolated-IR_column; %columnar IOR is lower than isolated 
mitochondria 
deltaIR = deltaIR/frames; %stepwise change in IR 
mito_ior = mito_ior+deltaIR*normrnd(1,.01); 
mito_ior = mito_ior.*mito_mask; 
  
%diameters become smaller (from .75 to ~.4) 
diam_column = .75; 
diam_isolated = .4; 
delta_diam = diam_isolated-diam_column; 
delta_diam = delta_diam/frames; 
mito_diams = mito_diams+delta_diam*normrnd(1,.075); 
mito_diams = mito_diams.*mito_mask; 
  
end 
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3) mie_scatter.m 
Called by chain_maker_final.m 
 
function natural = mie_scatter(dia, lambda, nmed, nsph, angles, conc) 
%dia = [um]; lambda = [nm] 
  
    angles=angles;                      %SARis 
    nmed = nmed     ;                   % medium refractive index (water) 
    npar_real = real(nsph) ;            % particle refractive index 
(polystyrene) 
    npar_imag = imag(nsph)   ;          % imaginary component of npar 
    vf   = 0.05     ;                   % volume fraction of spheres in 
medium (analogous to concentration)  
                                        %%%%% volume of sphere = (4/3)*pi^3 
                                         
    m1 = npar_real + npar_imag  ;       % (complex) refractive index of the 
spheres 
    m = m1/nmed                 ;       % m - relative (to the medium) 
complex refractive index 
    sa = linspace(-179,180,angles)         ;       % scattering angle range -
- add linspace 
  
    lambda_nm = [lambda]             ;    % [nm] wavelength of incident beam, 
we can also set this as a range 
    lambdalambda = lambda_nm/1000  ;    % [um] wavelength of incident beam 
    diadia = [dia]                 ;    % [um] sphere diameter, we can also 
set this as a range   
    % Calculates: Size parameter and Scattering Efficiency 
    k = (2*pi)/lambdalambda ;       %calculate wave number 
    sphr_rad = diadia/2     ;       %calculate sphere radius [um] 
    sp = k*sphr_rad         ;       %calculate sp 
    sp_nmed = sp*nmed       ;       %the site has this equation for the sp, 
so we will us it as well 
    x = sp_nmed             ;       %also denote "x" as size parameter  
    result_1 = Mie(m,x) ; 
    qsca=result_1(5); 
     
%% 
% This [for loop] is really only applicable (???) when running through a 
range of 
% diameters and wavelengths  
  
musgp = zeros(length(lambdalambda),length(diadia),3); 
  
for j=1:length(diadia) 
    dia = diadia(j); 
     
    for i=1:length(lambdalambda) 
        lambda = lambdalambda(i); 
         
        for k = 1:length(lambdalambda) 
            x(k) = (2*pi)/lambda ; 
        end 
  
        musgp(i,j,:) = getMieScatter(lambda, dia, vf, m,nmed); 
39 
  
    end % i 
     
end % j 
 x = sp_nmed             ;       %also denote "x" as size parameter  
  
 %% Calculate S1, S2 and Natural  
  
for i = 1:length(sa) ; 
     
    u(i) =   cosd(sa(i))     ;   
     
    S1S2 = Mie_S12(m,x,u(i)) ; 
    S1(i)=S1S2(1); 
    S2(i)=S1S2(2); 
     
    natural(i) = (abs(S1(i)^2)+abs(S2(i)^2))/(pi*((sp_nmed)*(sp_nmed))*qsca)    
; 
    NATURAL(i) = [natural(i)] / 2   ; 
                            
end 
  
  
%set up correspondance matrix 
    Matrix_saNatural = zeros(2,angles)    ; 
    Matrix_saNatural(1,:) = sa         ; 
    Matrix_saNatural(2,:) = NATURAL    ; 
     
    natural = Matrix_saNatural; 
  
function result = Mie(m, x) 
%The following text lists the Program to compute the Mie Efficiencies: 
  
% Computation of Mie Efficiencies for given 
% complex refractive-index ratio m=m'+im" 
% and size parameter x=k0*a, where k0= wave number in ambient 
% medium, a=sphere radius, using complex Mie Coefficients 
% an and bn for n=1 to nmax, 
% s. Bohren and Huffman (1983) BEWI:TDD122, p. 103,119-122,477. 
% Result: m', m", x, efficiencies for extinction (qext), 
% scattering (qsca), absorption (qabs), backscattering (qb), 
% asymmetry parameter (asy=<costeta>) and (qratio=qb/qsca). 
% Uses the function "Mie_abcd" for an and bn, for n=1 to nmax. 
% C. M‰tzler, May 2002. 
if x==0 % To avoid a singularity at x=0 
result=[real(m) imag(m) 0 0 0 0 0 0 1.5]; 
elseif x>0 % This is the normal situation 
nmax=round(2+x+4*x^(1/3)); 
n1=nmax-1; 
n=(1:nmax);cn=2*n+1; c1n=n.*(n+2)./(n+1); c2n=cn./n./(n+1); 
x2=x*x; 
f=Mie_abcd(m,x); 
anp=(real(f(1,:))); anpp=(imag(f(1,:))); 
bnp=(real(f(2,:))); bnpp=(imag(f(2,:))); 
g1(1:4,nmax)=[0; 0; 0; 0]; % displaced numbers used for 
g1(1,1:n1)=anp(2:nmax); % asymmetry parameter, p. 120 
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g1(2,1:n1)=anpp(2:nmax); 
g1(3,1:n1)=bnp(2:nmax); 
g1(4,1:n1)=bnpp(2:nmax); 
dn=cn.*(anp+bnp); 
q=sum(dn); 
qext=2*q/x2; 
en=cn.*(anp.*anp+anpp.*anpp+bnp.*bnp+bnpp.*bnpp); 
q=sum(en); 
qsca=2*q/x2; 
qabs=qext-qsca; 
fn=(f(1,:)-f(2,:)).*cn; 
gn=(-1).^n; 
f(3,:)=fn.*gn; 
q=sum(f(3,:)); 
qb=q*q'/x2; 
asy1=c1n.*(anp.*g1(1,:)+anpp.*g1(2,:)+bnp.*g1(3,:)+bnpp.*g1(4,:)); 
asy2=c2n.*(anp.*bnp+anpp.*bnpp); 
asy=4/x2*sum(asy1+asy2)/qsca; 
qratio=qb/qsca; 
result=[real(m) imag(m) x qext qsca qabs qb asy qratio]; 
end; 
function S1S2 = Mie_S12(m,x,u) 
% Computation of Mie Scattering functions S1 and S2 
% for complex refractive index m=m'+im", 
% size parameter x=k0*a, and u=cos(scattering angle), 
% where k0=vacuum wave number, a=sphere radius; 
% s. p. 111-114, Bohren and Huffman (1983) BEWI:TDD122 
% C. M‰tzler, May 2002 
  
nmax=round(2+x+4*x^(1/3)); 
abcd=Mie_abcd(m,x);             %compute the bessel coefficients  
an=abcd(1,:); 
bn=abcd(2,:); 
pt=Mie_pt(u,nmax); 
pin =pt(1,:); 
tin=pt(2,:); 
n=(1:nmax); 
n2=(2*n+1)./(n.*(n+1)); 
pin=n2.*pin; 
tin=n2.*tin; 
S1=(an*pin'+bn*tin'); 
S2=(an*tin'+bn*pin'); 
  
  
S1S2=[S1;S2]; 
function result = Mie_abcd(m, x) 
%The following text lists the basic program to compute the Mie Coefficients 
an, bn, 
%cn, dn and to produce a matrix of nmax column vectors [an; bn; cn; dn]: 
  
% Computes a matrix of Mie coefficients, a_n, b_n, c_n, d_n, 
% of orders n=1 to nmax, complex refractive index m=m'+im", 
% and size parameter x=k0*a, where k0= wave number 
% in the ambient medium, a=sphere radius; 
% p. 100, 477 in Bohren and Huffman (1983) BEWI:TDD122 
% C. M‰tzler, June 2002 
nmax=round(2+x+4*x^(1/3)); 
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n=(1:nmax); nu = (n+0.5); z=m.*x; m2=m.*m; 
sqx= sqrt(0.5*pi./x); sqz= sqrt(0.5*pi./z); 
bx = besselj(nu, x).*sqx; 
bz = besselj(nu, z).*sqz; 
yx = bessely(nu, x).*sqx; 
hx = bx+i*yx; 
b1x=[sin(x)/x, bx(1:nmax-1)]; 
b1z=[sin(z)/z, bz(1:nmax-1)]; 
y1x=[-cos(x)/x, yx(1:nmax-1)]; 
h1x= b1x+i*y1x; 
ax = x.*b1x-n.*bx; 
az = z.*b1z-n.*bz; 
ahx= x.*h1x-n.*hx; 
an = (m2.*bz.*ax-bx.*az)./(m2.*bz.*ahx-hx.*az); 
bn = (bz.*ax-bx.*az)./(bz.*ahx-hx.*az); 
cn = (bx.*ahx-hx.*ax)./(bz.*ahx-hx.*az); 
dn = m.*(bx.*ahx-hx.*ax)./(m2.*bz.*ahx-hx.*az); 
result=[an; bn; cn; dn]; 
function musgp = getMieScatter(lambda, dia, fv, npar,nmed) 
% function musgp = getMieScatter(lambda, dia, fv) 
%  fv            = volume fraction of spheres in medium (eg., fv = 0.05) 
%  lambda        = wavelength in um (eg., lambda = 0.633) 
%  dia           = sphere diameter in um (eg., dia_um = 0.0500) 
%  npar          = particle refractive index (eg. polystyrene = 1.57) 
%  nmed          = medium refractive index (eg., water = 1.33) 
%                  Note: npar and nmed can be imaginary numbers. 
%  returns musgp = [mus g musp]   
%       mus      = scattering coefficient [cm^-1] 
%       g        = anisotropy of scattering [dimensionless] 
%       musp     = reduced scattering coefficient [cm^-1] 
%  Uses 
%       Mie.m, which uses mie_abcd.m, from Maetzler 2002 
%        
% - Steven Jacques, 2009 
  
Vsphere = 4/3*pi*(dia/2)^3;     % volume of sphere 
rho     = fv/Vsphere;           % #/um^3, concentration of spheres 
  
m = npar/nmed;                  % ratio of refractive indices 
x = pi*dia/(lambda/nmed);       % ratio circumference/wavelength in medium 
  
u = Mie(m, x)';                 % <----- Matlzer's subroutine 
% u = [real(m) imag(m) x qext qsca qabs qb asy qratio]; 
  
qsca = u(5);                    % scattering efficiency, Qsca 
g    = u(8);                    % anisotropy, g 
  
A       = pi*dia^2/4;           % geometrical cross-sectional area, um^2 
sigma_s = qsca*A;               % scattering cross-section, um^2 
mus     = sigma_s*rho*1e4;      % scattering coeff. cm^-1 
musp    = mus*(1-g);            % reduced scattering coeff. cm^-1 
  
if 1 % 1 = print full report, 0 = disable 
    disp('----- choice:') 
    disp(sprintf('lambda  \t= %0.3f um', lambda)) 
    disp(sprintf('dia     \t= %0.3f um', dia)) 
    disp(sprintf('rho     \t= %0.3f #/um^3', rho)) 
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    disp(sprintf('npar    \t= %0.3f', npar)) 
    disp(sprintf('nmed    \t= %0.3f', nmed)) 
    disp('----- result:') 
    disp(sprintf('real(m) \t= %0.3f', u(1))) 
    disp(sprintf('imag(m) \t= %0.3e', u(2))) 
    disp(sprintf('x       \t= %0.3e', u(3))) 
    disp(sprintf('qext    \t= %0.3e', u(4))) 
    disp(sprintf('qsca    \t= %0.3e', u(5))) 
    disp(sprintf('qabs    \t= %0.3e', u(6))) 
    disp(sprintf('qb      \t= %0.3e', u(7))) 
    disp(sprintf('asy     \t= %0.4f', u(8))) 
    disp(sprintf('qratio  \t= %0.3e', u(9))) 
    disp('----- optical properties:') 
    disp(sprintf('mus     \t= %0.3f cm^-1', mus)) 
    disp(sprintf('g       \t= %0.4f', g)) 
    disp(sprintf('musp    \t= %0.3f cm^-1', musp)) 
end 
  
musgp= real([mus g musp]); 
function result=Mie_pt(u,nmax) 
% The following text lists the program to compute a matrix of ?n and ?n 
functions for 
% n=1 to nmax: 
% pi_n and tau_n, -1 <= u= cos? <= 1, n1 integer from 1 to nmax 
% angular functions used in Mie Theory 
% Bohren and Huffman (1983), p. 94 - 95 
p(1)=1; 
t(1)=u; 
p(2)=3*u; 
t(2)=3*cos(2*acos(u)); 
for n1=3:nmax, 
p1=(2*n1-1)./(n1-1).*p(n1-1).*u; 
p2=n1./(n1-1).*p(n1-2); 
p(n1)=p1-p2; 
t1=n1*u.*p(n1); 
t2=(n1+1).*p(n1-1); 
t(n1)=t1-t2; 
end; 
result=[p;t]; 
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